StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
MEDS.ST$22.10+0.45%
Fair $22.10+0.0%

MEDS.ST

MEDS.ST

Consumer Cyclical / Internet RetailStockholm

$22.10

+0.10 (+0.45%)

Fairly Valued+0.0%Fair Value $22.10Fund rank 25/100 · Data gapFallback financials|
SA 28/D
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 19%

FCF escenarios

weak_data · normalized FCF $-28.8M · quality 43.7/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 8/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

28/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · MEDS.STLocal privado en este navegador · MEDS.ST
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$410M

P/E

56.7x

↑

EV/EBITDA

20.5x

↑

ROE

6.0%

↑

Gross Margin

27.6%

↓

Debt/Equity

0.05

↓
52-Week Range$22
$21$77

TradingView lightweight chart

MEDS.ST price, volumen y niveles de valoración

Último $22.10Periodo -61.9%
Fair value: $22.10

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2025 · 4 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

-2.9%

FCF / Net income

-3.73x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.01B · net income $7.7M · FCF $-28.8M

2021-FY → 2025-FY

Gross margin

27.6%— pts

Operating margin

-0.2%— pts

Net margin

0.8%— pts

FCF margin

-2.9%— pts
MetricTTM
2025
2024
2023
2021
Income Statement
Revenue$1.01B$1.01B$829.2M$655.2M—
Net Income$7.7M$7.7M$-10.4M$-51.0M—
EBITDA$18.2M$18.2M$13.6M$-27.0M—
EPS0.430.43-0.60-3.05—
Gross Margin27.6%27.6%28.0%28.5%—
Operating Margin-0.2%-0.2%-1.0%-7.5%—
Net Margin0.8%0.8%-1.3%-7.8%—
Balance Sheet
Debt/Equity0.050.050.410.950.45
Current Ratio1.611.61———
Cash Flow
Free Cash Flow$-28.8M$-28.8M$12.1M$-58.3M—
Returns
ROE6.0%6.0%-17.7%-74.6%—
Valuation
P/E56.6756.67———
EV/EBITDA20.4520.45———
P/B3.203.20———
Growth & Yield
Revenue Growth21.4%21.4%26.6%——
EPS Growth171.7%171.7%80.3%——

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

65.8%

muy exigente

EPS terminal req.

$1.96

Spread vs growth

105.8%

5Y implied EPS CAGR

40.7%

muy exigente

EPS terminal req.

$2.37

Spread vs growth

130.9%

10Y implied EPS CAGR

24.4%

exigente

EPS terminal req.

$3.82

Spread vs growth

147.3%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total -61.9%

Total return

-61.9%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.60 → 0.43

Residual

-61.9%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-61.9%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.